| European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ... Blood, The Journal of the American Society of Hematology 122 (6), 872-884, 2013 | 2552 | 2013 |
| Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL … T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ... Blood 108 (1), 28-37, 2006 | 1527 | 2006 |
| BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European … S Soverini, A Hochhaus, FE Nicolini, F Gruber, T Lange, G Saglio, F Pane, ... Blood, The Journal of the American Society of Hematology 118 (5), 1208-1215, 2011 | 722 | 2011 |
| Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia S Soverini, S Colarossi, A Gnani, G Rosti, F Castagnetti, A Poerio, ... Clinical Cancer Research 12 (24), 7374-7379, 2006 | 636 | 2006 |
| Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia R Foa, A Vitale, M Vignetti, G Meloni, A Guarini, MS De Propris, L Elia, ... Blood, The Journal of the American Society of Hematology 118 (25), 6521-6528, 2011 | 489 | 2011 |
| ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression … S Soverini, G Martinelli, G Rosti, S Bassi, M Amabile, A Poerio, B Giannini, ... Journal of clinical oncology 23 (18), 4100-4109, 2005 | 472 | 2005 |
| Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase T Hughes, G Saglio, S Branford, S Soverini, DW Kim, MC Müller, ... Journal of clinical oncology 27 (25), 4204, 2009 | 387 | 2009 |
| IKZF1 (Ikaros) Deletions in BCR-ABL1–Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative … G Martinelli, I Iacobucci, CT Storlazzi, M Vignetti, F Paoloni, D Cilloni, ... Journal of Clinical Oncology 27 (31), 5202-5207, 2009 | 361 | 2009 |
| Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia G Rosti, F Palandri, F Castagnetti, M Breccia, L Levato, G Gugliotta, ... Blood, The Journal of the American Society of Hematology 114 (24), 4933-4938, 2009 | 287 | 2009 |
| Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute … I Iacobucci, CT Storlazzi, D Cilloni, A Lonetti, E Ottaviani, S Soverini, ... Blood, The Journal of the American Society of Hematology 114 (10), 2159-2167, 2009 | 266 | 2009 |
| BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships JS Khorashad, TW Kelley, P Szankasi, CC Mason, S Soverini, LT Adrian, ... Blood, The Journal of the American Society of Hematology 121 (3), 489-498, 2013 | 252 | 2013 |
| The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study M Baccarani, D Cilloni, M Rondoni, E Ottaviani, F Messa, S Merante, ... haematologica 92 (9), 1173-1179, 2007 | 242 | 2007 |
| Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain S Soverini, S Colarossi, A Gnani, F Castagnetti, G Rosti, C Bosi, S Paolini, ... Haematologica 92 (3), 401-404, 2007 | 218 | 2007 |
| Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with … S Soverini, A Gnani, S Colarossi, F Castagnetti, E Abruzzese, S Paolini, ... Blood, The Journal of the American Society of Hematology 114 (10), 2168-2171, 2009 | 200 | 2009 |
| Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia S Soverini, S Branford, FE Nicolini, M Talpaz, MWN Deininger, ... Leukemia research 38 (1), 10-20, 2014 | 197 | 2014 |
| Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma PL Zinzani, A Pulsoni, A Perrotti, S Soverini, F Zaja, A De Renzo, S Storti, ... Journal of clinical oncology 22 (13), 2654-2661, 2004 | 192 | 2004 |
| Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Baccarani, S Pileri, JL Steegmann, M Muller, S Soverini, M Dreyling Annals of oncology 23, vii72-vii77, 2012 | 189 | 2012 |
| Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain S Soverini, C De Benedittis, K Machova Polakova, A Brouckova, D Horner, ... Blood, The Journal of the American Society of Hematology 122 (9), 1634-1648, 2013 | 183 | 2013 |
| Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous … S Soverini, M Cavo, C Cellini, C Terragna, E Zamagni, D Ruggeri, ... Blood 102 (5), 1588-1594, 2003 | 163 | 2003 |
| Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new … I Iacobucci, A Lonetti, F Messa, D Cilloni, F Arruga, E Ottaviani, S Paolini, ... Blood, The Journal of the American Society of Hematology 112 (9), 3847-3855, 2008 | 148 | 2008 |
